Mizuho initiated coverage on shares of DexCom (NASDAQ:DXCM – Free Report) in a report issued on Thursday, MarketBeat Ratings reports. The firm issued an outperform rating and a $85.00 price objective on the medical device company’s stock.
DXCM has been the topic of a number of other reports. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Cfra Research upgraded DexCom to a “hold” rating in a research note on Friday, March 21st. Canaccord Genuity Group raised their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.00.
Check Out Our Latest Stock Report on DexCom
DexCom Trading Down 1.7 %
DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities research analysts forecast that DexCom will post 2.03 earnings per share for the current year.
Insider Activity at DexCom
In other news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares of the company’s stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock valued at $8,044,178 in the last quarter. Insiders own 0.30% of the company’s stock.
Institutional Trading of DexCom
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc acquired a new stake in DexCom during the 4th quarter worth approximately $25,000. Private Trust Co. NA lifted its holdings in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Optiver Holding B.V. bought a new stake in shares of DexCom in the fourth quarter worth $33,000. TD Private Client Wealth LLC increased its holdings in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the period. Finally, Larson Financial Group LLC raised its position in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Stories
- Five stocks we like better than DexCom
- 5 Top Rated Dividend Stocks to Consider
- Robinhood Strategies Could Be a Game-Changer for Young Investors
- What Are Treasury Bonds?
- Are These 3 Retail Stocks Oversold or Really in Trouble?
- How to Buy Gold Stock and Invest in Gold
- IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.